



UNITED STATES  
**NUCLEAR REGULATORY COMMISSION**  
REGION I  
475 ALLENDALE ROAD  
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

August 9, 2006

Docket No. 03002431  
Control No. 138938

License No. 29-01101-03

Jeffrey Goodwin  
Chief Executive Officer  
Warren Hospital  
185 Roseberry Street  
Phillipsburg, NJ 08865

SUBJECT: WARREN HOSPITAL, LICENSE AMENDMENT, CONTROL NO. 138938

Dear Mr. Goodwin:

This refers to your license amendment request dated May 25, 2006. Enclosed with this letter is the amended license. We have approved Drs. Little, Mascarenhas, Singh, Elmi, C. Patel, Rohatgi, and Khalighi as authorized user under 35.100 and 35.200.

Please note that Dr. Arthur Popkave is not an Authorized User on the license # 29-30622-01 and Dr. Pradeep S. Ghia is not an Authorized User on the license # 37-30276-01 as stated in your letter dated May 25, 2006.

Please note that in support of your request to authorize Drs. Arthur Popkave, Nainesh Patel, Devendra K. Amin and Pradeep S. Ghia for materials permitted under 10 CFR 35.100 and 35.200, please provide one of the following, as applicable:

10 CFR 35.290 Training for imaging and localization studies.

Except as provided in § 35.57, the licensee shall require an authorized user of unsealed byproduct material for the uses authorized under § 35.200 to be a physician who—

(a) Is certified by a medical specialty board whose certification process has been recognized by the Commission or an Agreement State and who meets the requirements in paragraph (c)(2) of this section. (The names of board certifications which have been recognized by the Commission or an Agreement State will be posted on the NRC's Web page.) To have its certification process recognized, a specialty board shall require all candidates for certification to:

(1) Complete 700 hours of training and experience in basic radionuclide handling techniques and radiation safety applicable to the medical use of unsealed byproduct material for imaging and localization studies that includes the topics listed in paragraphs (c)(1)(i) and (c)(1)(ii) of this section; and

(2) Pass an examination, administered by diplomates of the specialty board, which assesses knowledge and competence in radiation safety, radionuclide handling, and quality control; or

(b) Is an authorized user under § 35.390 and meets the requirements in § 35.290(c)(1)(ii)(G), or equivalent Agreement State requirements; or

(c)(1) Has completed 700 hours of training and experience, including a minimum of 80 hours of classroom and laboratory training, in basic radionuclide handling techniques applicable to the medical use of unsealed byproduct material for imaging and localization studies. The training and experience must include, at a minimum—

(i) Classroom and laboratory training in the following areas—

(A) Radiation physics and instrumentation;

(B) Radiation protection;

(C) Mathematics pertaining to the use and measurement of radioactivity;

(D) Chemistry of byproduct material for medical use;

(E) Radiation biology; and

(ii) Work experience, under the supervision of an authorized user, who meets the requirements in §§ 35.290, or 35.290(c)(1)(ii)(G), and 35.390, or equivalent Agreement State requirements, involving--

(A) Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys;

(B) Performing quality control procedures on instruments used to determine the activity of dosages and performing checks for proper operation of survey meters;

(C) Calculating, measuring, and safely preparing patient or human research subject dosages;

(D) Using administrative controls to prevent a medical event involving the use of unsealed byproduct material;

(E) Using procedures to safely contain spilled radioactive material and using proper decontamination procedures;

(F) Administering dosages of radioactive drugs to patients or human research subjects; and

(G) Eluting generator systems appropriate for preparation of radioactive drugs for imaging and localization studies, measuring and testing the eluate for radionuclidic purity, and processing the eluate with reagent kits to prepare labeled radioactive drugs; and

J. Goodwin  
Warren Hospital

3

(2) Has obtained written attestation, signed by a preceptor authorized user who meets the requirements in §§ 35.290, or 35.390 and 35.290(c)(1)(ii)(G), or equivalent Agreement State requirements, that the individual has satisfactorily completed the requirements in paragraph (a)(1) or (c)(1) of this section and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under §§ 35.100 and 35.200.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Current NRC regulations and guidance are included on the NRC's website at [www.nrc.gov](http://www.nrc.gov); select **Nuclear Materials; Medical, Academic, and Industrial Uses of Nuclear Material**; then **Toolkit Index Page**. Or you may obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-888-293-6498. The GPO is open from 7:00 a.m. to 8:00 p.m. EST, Monday through Friday (except Federal holidays).

Thank you for your cooperation.

Sincerely,

***Original signed by Shirley Xu***

Shirley Xu  
Health Physicist  
Medical Branch  
Division of Nuclear Materials Safety

Enclosure:  
Amendment No. 28

cc:  
Mitchell Rabinowitz, M.D., Radiation Safety Officer

J. Goodwin  
Warren Hospital

4

DOCUMENT NAME: G:\Docs\Mailed\Lic Cvr Letter\I29-01101-03.138938.08112006.wpd

**SUNSI Review Complete: SXu**

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

|        |          |                                       |         |                          |         |                          |  |                          |
|--------|----------|---------------------------------------|---------|--------------------------|---------|--------------------------|--|--------------------------|
| OFFICE | DNMS/RI  | <input checked="" type="checkbox"/> N | DNMS/RI | <input type="checkbox"/> | DNMS/RI | <input type="checkbox"/> |  | <input type="checkbox"/> |
| NAME   | SXu/SX   |                                       |         |                          |         |                          |  |                          |
| DATE   | 8/9/2006 |                                       |         |                          |         |                          |  |                          |

OFFICIAL RECORD COPY

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

|   |   |
|---|---|
| <p>Licensee</p> <p>1. Warren Hospital</p> <p>2. 185 Roseberry Street<br/>Phillipsburg, New Jersey 08865</p> | <p>In accordance with the letter dated May 25, 2006,</p> <p>3. License number 29-01101-03 is amended in its entirety to read as follows:</p> <p>4. Expiration date August 31, 2012</p> <p>5. Docket No. 030-02431<br/>Reference No.</p> |
|---|---|

- |   |  |  |
|---|--|--|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material included in 10 CFR 35.100</p> <p>B. Any byproduct material included in 10 CFR 35.200</p> <p>C. Iodine 125</p> | <p>7. Chemical and/or physical form</p> <p>A. Any radiopharmaceutical included in 10 CFR 35.100</p> <p>B. Any radiopharmaceutical included in 10 CFR 35.200</p> <p>C. Any brachytherapy source identified in 10 CFR 35.400</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 1000 millicuries</p> |
|---|--|--|

## 9. Authorized use:

- A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.
- B. Any imaging and localization procedure approved in 10 CFR 35.200.
- C. Any brachytherapy procedure approved in 10 CFR 35.400.

**CONDITIONS**

10. Licensed material may be used only at the licensee's facilities located at 185 Roseberry Street, Phillipsburg, New Jersey.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
29-01101-03Docket or Reference Number  
030-02431

Amendment No. 28

11. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for the materials and uses indicated:

| <u>Authorized Users</u>   | <u>Material and Use</u> |
|---------------------------|-------------------------|
| Mitchell Rabinowitz, M.D. | 35.100; 35.200          |
| Joseph M. Bucich, M.D.    | 35.100; 35.200          |
| Patrick M. Inverso, M.D.  | 35.100; 35.200          |
| Kenneth A. Cohen, M.D.    | 35.100; 35.200          |
| Stuart Miller, M.D.       | 35.100; 35.200          |
| Matthew S. Pollack, M.D.  | 35.100; 35.200          |
| Thomas Little, M.D.       | 35.100; 35.200          |
| Daniel Mascarenhas, M.D.  | 35.100; 35.200          |
| Narpinder Singh, M.D.     | 35.100; 35.200          |
| Farhad Elmi, M.D.         | 35.100; 35.200          |
| Chandulal Patel, M.D.     | 35.100; 35.200          |
| Rajeev Rohatgi, M.D.      | 35.100; 35.200          |
| Koroush Khalighi, M.D.    | 35.100; 35.200          |
| Aruna Patel, M.D.         | 35.400                  |
| Stewart Berkowitz, M.D.   | 35.400                  |

12. The Radiation Safety Officer for this license is Mitchell Rabinowitz, M.D.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), 40.36(b), and 70.25(d) for establishing financial assurance for decommissioning.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
29-01101-03Docket or Reference Number  
030-02431

Amendment No. 28

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated June 29, 1991
- B. Letter dated June 17, 1992
- C. Letter dated July 15, 1996
- D. Letter dated November 11, 1996
- E. Letter dated April 28, 1997
- F. Letter dated November 28, 2000 except Quality Management Program
- G. Letter dated January 8, 2001



For the U.S. Nuclear Regulatory Commission

Date August 9, 2006

By

***Original signed by Shirley Xu***

Shirley Xu  
Medical Branch  
Division of Nuclear Materials Safety  
Region I  
King of Prussia, Pennsylvania 19406